Nuformix PLC Updates Share Admission Date and Expands Capital

The latest update is out from Nuformix Plc ( (GB:NFX) ).

Nuformix PLC announced a correction to its earlier statement regarding the exercise of broker warrants, clarifying that the admission of new ordinary shares to the London Stock Exchange will commence on 22 April 2025, rather than the previously stated date. The issuance of 26,400,000 new shares at 0.05 pence each will raise £13,200 for the company, increasing its total voting rights to 1,695,709,368 shares, which stakeholders can use for interest calculations under FCA rules.

Spark’s Take on GB:NFX Stock

According to Spark, TipRanks’ AI Analyst, GB:NFX is a Underperform.

Nuformix Plc faces severe financial challenges with no revenue generation and persistent losses, which significantly impact its stock score. While recent corporate events offer some optimism, the lack of profitability and negative valuation metrics overshadow these positives, leading to a low overall score.

To see Spark’s full report on GB:NFX stock, click here.

More about Nuformix Plc

Nuformix is a pharmaceutical development company that focuses on addressing unmet medical needs in fibrosis and oncology through drug repurposing. The company leverages its expertise in creating novel drug forms with improved properties to develop differentiated products, offering new commercial opportunities. Nuformix has a pipeline of preclinical assets with potential for significant value and early licensing opportunities.

YTD Price Performance: 134.04%

Average Trading Volume: 61,662,697

Technical Sentiment Signal: Buy

Current Market Cap: £1.84M

See more insights into NFX stock on TipRanks’ Stock Analysis page.